What one share of MaxCyte holds
We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development.
MaxCyte’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.29 |
|---|---|
| Profit | −$0.33 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.22 |
| Cash and investments | $0.14 |
| Book value | $1.50 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.38 | −$0.23 | $0.02 | −$0.18 | — | $0.24 |
| 2020 | $0.38 | −$0.17 | $0.03 | −$0.16 | — | $0.43 |
| 2021 | $0.37 | −$0.21 | $0.04 | −$0.16 | — | $2.60 |
| 2022 | $0.44 | −$0.23 | $0.18 | −$0.33 | — | $2.48 |
| 2023 | $0.40 | −$0.37 | $0.04 | −$0.25 | — | $2.23 |
| 2024 | $0.37 | −$0.39 | $0.02 | −$0.28 | — | $1.95 |
| 2025 | $0.31 | −$0.42 | $0.02 | −$0.34 | — | $1.61 |
Common questions about MaxCyte
How much does one share of MaxCyte earn?
Over the last 12 months, MaxCyte lost $0.33 for each share on $0.29 of sales.
Does MaxCyte pay a dividend?
MaxCyte didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is MaxCyte’s book value per share?
MaxCyte’s book value is $1.50 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of MaxCyte have?
Each share of MaxCyte has $0.14 of cash and investments, as of June 30, 2026.
What is MaxCyte’s free cash flow per share?
−$0.22 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has MaxCyte bought back shares?
MaxCyte’s share count rose about 89% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.